To address this knowledge gap, we analyzed data from a Japanese hospital-based claims database to clarify the treatment patterns and characteristics of high-risk early-stage breast cancer patients not receiving anti-HER2 therapy but undergoing perioperative systemic anthracycline/taxane therapy. This evidence concerns the gene ERBB2 and breast carcinoma.